200 related articles for article (PubMed ID: 26001533)
1. Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung.
Lee MS; Liu CY; Su L; Christiani DC
Lung Cancer; 2015 Jul; 89(1):8-12. PubMed ID: 26001533
[TBL] [Abstract][Full Text] [Related]
2. Genotypes and haplotypes of ERCC1 and ERCC2/XPD genes predict levels of benzo[a]pyrene diol epoxide-induced DNA adducts in cultured primary lymphocytes from healthy individuals: a genotype-phenotype correlation analysis.
Zhao H; Wang LE; Li D; Chamberlain RM; Sturgis EM; Wei Q
Carcinogenesis; 2008 Aug; 29(8):1560-6. PubMed ID: 18635523
[TBL] [Abstract][Full Text] [Related]
3. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
4. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
Lu X; Xiao S; Jin C; van der Straaten T; Li X
J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
[TBL] [Abstract][Full Text] [Related]
6. ERCC1 and ERCC2 haplotype modulates induced BPDE-DNA adducts in primary cultured lymphocytes.
Lu X; Liu Y; Yu T; Xiao S; Bao X; Pan L; Zhu G; Cai Y; Liu Q; Jin C; Yang J; Wu S; An L; van der Straaten T
PLoS One; 2013; 8(4):e60006. PubMed ID: 23593158
[TBL] [Abstract][Full Text] [Related]
7. Association of genetic polymorphisms in ERCC1 and ERCC2/XPD with risk of chronic benzene poisoning in a Chinese occupational population.
Xiao S; Gao L; Liu Y; Yu T; Jin C; Pan L; Zhu G; Lu X
Mutat Res; 2013 Feb; 751(1):52-8. PubMed ID: 23147699
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
[TBL] [Abstract][Full Text] [Related]
9. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Yang Y; Xian L
Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
[TBL] [Abstract][Full Text] [Related]
10. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract][Full Text] [Related]
12. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.
Yin M; Yan J; Voutsina A; Tibaldi C; Christiani DC; Heist RS; Rosell R; Booton R; Wei Q
Lung Cancer; 2011 Jun; 72(3):370-7. PubMed ID: 21075476
[TBL] [Abstract][Full Text] [Related]
13. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
14. ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females.
Yin Z; Su M; Li X; Li M; Ma R; He Q; Zhou B
J Exp Clin Cancer Res; 2009 Dec; 28(1):153. PubMed ID: 20003391
[TBL] [Abstract][Full Text] [Related]
15. [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
Ai Zheng; 2005 Dec; 24(12):1510-3. PubMed ID: 16351803
[TBL] [Abstract][Full Text] [Related]
16. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
17. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck.
Sturgis EM; Dahlstrom KR; Spitz MR; Wei Q
Arch Otolaryngol Head Neck Surg; 2002 Sep; 128(9):1084-8. PubMed ID: 12220217
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in nucleotide excision repair genes, polycyclic aromatic hydrocarbon-DNA adducts, and breast cancer risk.
Crew KD; Gammon MD; Terry MB; Zhang FF; Zablotska LB; Agrawal M; Shen J; Long CM; Eng SM; Sagiv SK; Teitelbaum SL; Neugut AI; Santella RM
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2033-41. PubMed ID: 17932351
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms of DNA repair genes: ERCC1 G19007A and ERCC2/XPD C22541A in a northeastern Chinese population.
Yin J; Li J; Vogel U; Wang H
Biochem Genet; 2005 Oct; 43(9-10):543-8. PubMed ID: 16341770
[TBL] [Abstract][Full Text] [Related]
20. DNA Repair Genetics and the Risk of Radiation Pneumonitis in Patients With Lung Cancer: A Systematic Review and Meta-analysis.
Yiu WS; Chu TSM; Meng Y; Kong FS
Clin Oncol (R Coll Radiol); 2024 Jul; 36(7):e182-e196. PubMed ID: 38653664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]